These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1715125)

  • 1. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
    Goldberg AD; Nicklas J; Goldstein S
    Am J Cardiol; 1991 Sep; 68(6):631-6. PubMed ID: 1715125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
    Massie B; Bourassa M; DiBianco R; Hess M; Konstam M; Likoff M; Packer M
    Circulation; 1985 May; 71(5):963-71. PubMed ID: 3886191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
    Lubsen J; Just H; Hjalmarsson AC; La Framboise D; Remme WJ; Heinrich-Nols J; Dumont JM; Seed P
    Heart; 1996 Sep; 76(3):223-31. PubMed ID: 8868980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study.
    DiBianco R; Shabetai R; Silverman BD; Leier CV; Benotti JR
    J Am Coll Cardiol; 1984 Nov; 4(5):855-66. PubMed ID: 6386932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
    Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
    Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment.
    Dubourg O; Delorme G; Hardy A; Beauchet A; Tarral A; Bourdarias JP
    Int J Cardiol; 1990 Jul; 28 Suppl 1():S33-42; discussion S43. PubMed ID: 2145237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of digitalis on left ventricular functional response to exercise in congestive heart failure.
    Morisco C; Cuocolo A; Romano M; Nappi A; Iaccarino G; Volpe M; Salvatore M; Trimarco B
    Am J Cardiol; 1996 Mar; 77(7):480-5. PubMed ID: 8629588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group.
    Narahara KA
    Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
    Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
    N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
    Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.
    Uretsky BF; Young JB; Shahidi FE; Yellen LG; Harrison MC; Jolly MK
    J Am Coll Cardiol; 1993 Oct; 22(4):955-62. PubMed ID: 8409069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
    Colucci WS; Sonnenblick EH; Adams KF; Berk M; Brozena SC; Cowley AJ; Grabicki JM; Kubo SA; LeJemtel T; Littler WA
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):113A-118A. PubMed ID: 8376682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
    Packer M
    Am J Cardiol; 1989 Jan; 63(2):41A-45A. PubMed ID: 2642629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
    Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
    Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
    DiBianco R; Shabetai R; Kostuk W; Moran J; Schlant RC; Wright R
    N Engl J Med; 1989 Mar; 320(11):677-83. PubMed ID: 2646536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.